A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Latest Information Update: 13 Nov 2024
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; STK-012 (Primary)
- Indications Cervical cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Synthekine
- 08 Nov 2024 Results presented in the Synthekine Media Release.
- 08 Nov 2024 According to a Synthekine media release, company presented positive translational results from the Phase 1a dose escalation portion of a Phase 1a/1b clinical trial of STK-012 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston.
- 07 Nov 2024 Arms increased from 4 to 6. Drugs pemetrexed and carboplatin added newly.